July 1 2021

In 2017, the American Society of Clinical Oncology and the Ontario Health-Cancer Care Ontario's non–small cell lung cancer expert panel published a guideline with recommendations for systemic therapy for patients with stage IV NSCLC.

Targeted Therapies in Oncology spoke with Martin J. Edelman, MD, do uncover what is next for small cell lung cancer after PD-1 inhibitor indication have been withdrawn.

Clinical pathways in cancer care are beyond the “new” phase, but oncology practices and health systems are still learning all the ways they can bring greater standardization to care, eliminate unnecessary care, improve data collection, and drive value.

Both cancer and its treatments are highly symptomatic, making it difficult at times for clinicians to closely monitor every symptom a patient experiences outside the office walls.

The heterogeneity of tumors in gastrointestinal cancers continues to pose a challenge, according to Wells Messersmith, MD.

T-cell–targeted immunomodulators burst onto the scene a decade ago, and investigators turned their focus to immune checkpoints such as CTLA-4, PD-1, and PD-L1 to develop new cancer-fighting strategies.

Encouraging findings from an ongoing phase 1 trial evaluating an off-the-shelf, allogeneic CD30-CAR Epstein Barr virus–specific T-cell therapy, evaluated in patients with lymphoma.

Although the genetic makeup of biliary tract cancer is rich, only recently has the field been able to show the benefit of treating patients with effective targeted agents, in the advanced setting.

Safety and efficacy data for natural killer T (NKT) cells bolster the use of this cellular therapy in patients with stage IV relapsed/refractory neuroblastoma, according to early findings.

The rapid issuance of clinical trial guidance, trial modifications and emphasis on inclusivity of diverse racial and ethnic patient populations have opened the door for new opportunities for decentralized clinical trials and real-world data in a post-Covid-19 world

Th of plasma cell-free methylomes offers investigators a method to monitor tumor responses to treatment noninvasively, according to findings presented during the AACR Annual Meeting 2021.

Regardless of age the combination of ribociclib and endocrine therapy led to improved overall survival in pre- or postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Adding paclitaxel to the combination of trastuzumab and pertuzumab was associated with pathologic complete response and invasive disease-free survival in patients with HER2-positive breast cancer compared with the doublet alone.

According to Inge Marie Svane, MD, PhD, the truth about what drives tumor-infiltrating lymphocyte efficacy is not yet known, and more research is needed.

Treatment with atezolizumab plus carboplatin demonstrated early clinical activity in patients with metastatic invasive lobular breast cancer, with slight trends toward increased clinical benefit in patients with triple-negative ILC and responders with higher PD-L1 expression.

Adjuvant trastuzumab is showing promising long-term results in patients with HER2-positive early breast cancer, a population that is representative of most patients seen in clinical practice.

Oncoloytic viruses are an emerging class of cancer therapeutics that may provide a new strategy against malignant tumors.